Zevalin

Zevalin (ibritumomab tiuxetan) is an intravenous therapy designed for targeted treatment of certain blood cancers. It combines a monoclonal antibody with a radioactive isotope for precise cancer cell targeting. Suitable for patients requiring radioimmunotherapy. Short version: Zevalin ibritumomab tiuxetan radioimmunotherapy for blood cancer treatment.

Zevalin (ibritumomab tiuxetan) is primarily used to treat types of non-Hodgkin lymphoma, including relapsed or refractory cases. It is indicated for patients who have not responded adequately to other therapies. The drug targets CD20-positive B-cell lymphoma cells using a radioactive component. Patients often ask, what is Zevalin used for in cancer treatment.

As a radioimmunotherapy agent, Zevalin delivers radiation directly to cancerous B-cells while sparing healthy tissue. Common effects may include temporary reductions in blood cell counts due to bone marrow impact. Some patients experience mild fatigue or nausea during treatment. Effects vary and should be discussed with a healthcare provider.

Zevalin requires careful handling due to its radioactive properties; administration must be performed by trained professionals in a controlled setting. Patients should inform their provider of all current medications and medical conditions before treatment. Pregnant or breastfeeding individuals should avoid use. Regular blood monitoring is typically required during therapy.

Zevalin may interact with other drugs affecting bone marrow function or those metabolized by liver enzymes. Live vaccines should be avoided during and after treatment. Blood transfusions may require special timing due to potential interference. Patients on immunosuppressive therapy should discuss risks with their doctor. Alcohol use may exacerbate side effects.